Fosgonimeton is under clinical development by Athira Pharma and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 12% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Fosgonimeton’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fosgonimeton overview

Fosgonimeton is under development for the treatment of Alzheimer’s disease, diabetic neuropathy, Parkinson's disease dementia and dementia with lewy bodies. It is administered subcutaneously. The drug candidate acts by targeting hepatocyte growth factor and its receptor (MET).

Athira Pharma overview

Athira Pharma, is a biopharmaceutical company that develops small molecules to treat neurodegenerative diseases and restore neuronal health. It is investigating ATH-1017, a small molecule drug for the treatment of Alzheimer’s and Parkinson’s disease; ATH-1020 against neuropsychiatric disorders; and Early Compounds that is Neuropathic Pain. The company works in partnership with contract development and manufacturing organizations to manufacture and supply preclinical and clinical materials for development of product candidates. Athira Pharma is headquartered in Bothell, Washington, the US.

For a complete picture of Fosgonimeton’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.